Buy Ethocybin Cas 60480-02-6

Buy Ethocybin Cas 60480-02-6

Ethocybin also known as 4-phosphoryloxy-N,N-diethyltryptamine (4-PO-DET) or as CEY-19, is a psychedelic drug of the tryptamine and 4-hydroxytryptamine families related to the psilocybin-containing mushroom alkaloid psilocybin.^[1] It is assumed to act as a prodrug of 4-HO-DET (CZ-74) analogously to how psilocybin (4-PO-DMT) acts as a prodrug of psilocin (4-HO-DMT).^[1][6] The drug was first described in the literature by Albert Hofmann and colleagues at Sandoz by 1963.^[7][8]

Ethocybin may be dephosphorylated in vivo to 4-HO-DET (ethocin), analogously to how psilocybin (4-PO-DMT) is metabolized to psilocin (4-HO-DMT).^[9] This chemical reaction takes place under strongly acidic conditions or enzymatically by phosphatases in the body. 4-HO-DET acts as a partial agonist of the serotonin 5-HT_2A receptor.^[10][11]

Analogues of ethocybin include 4-HO-DET (ethocin), 4-AcO-DET (ethacetin), psilocybin (4-PO-DMT), psilocin (4-HO-DMT), baeocystin (4-PO-NMT), and aeruginascin (4-PO-TMT), among others.

Albert Hofmann and colleagues working at Sandoz were the first to synthesize and describe ethocybin (CEY-19) along with 4-HO-DET (CZ-74), which shortly followed his discovery of psilocin and psilocybin.^[7][8] They first described the drug in a patent by 1963.^[7][8] Along with 4-HO-DET, ethocybin was one of the earliest structurally modified or synthetic psychedelic tryptamines to be developed.^[2][5]

Ethocybin is not an explicitly nor implicitly controlled substance in Canada as of 2025.^[12]

Ethocybin is not an explicitly controlled substance in the United States.^[13] However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.

Ethocybin, under the code name CEY-19 and along with 4-HO-DET (CZ-74), has been studied in psychedelic-assisted psychotherapy.^[4][1][8]